Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis

Launched by UNITY HEALTH TORONTO · Jun 3, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a medication called semaglutide, which is a type of treatment known as a GLP-1 receptor agonist (GLP1RA). The main goal is to see if semaglutide is safe and tolerable for patients who are on maintenance dialysis due to chronic kidney disease and diabetes. Participants in the study will be randomly assigned to receive either the semaglutide treatment once a week or the usual care they are currently receiving. The study will last for 26 weeks, allowing researchers to gather important information about how well this medication works in this specific group of patients.

To be eligible for this trial, participants need to be at least 18 years old and have been undergoing dialysis (either hemodialysis or peritoneal dialysis) for at least 90 days. They should also have a diagnosis of type 2 diabetes and be able to give consent for themselves or have a representative do it for them. However, individuals with type 1 diabetes, certain recent health issues, or those who are pregnant cannot participate. This trial is currently not recruiting participants, but it represents an important step in understanding how to better manage diabetes for those with end-stage kidney disease.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age ≥ 18
• • 2. Receiving chronic maintenance hemodialysis or peritoneal dialysis for ≥ 90 days
• • 3. confirmed DM2 based on medical history and current or prior receipt of an oral hypoglycemic agent and/or insulin.
• • 4. Ability to provided informed consent or through their substitute decision maker
• Exclusion Criteria:
• • 1. Type 1 DM
• • 2. Use of a GLP-1-RA within 30 days prior to screening
• • 3. Personal or first-degree relative(s) with a history of type 2 multiple endocrine neoplasia syndrome or medullary thyroid cancer, or acute pancreatitis (within 180 days of study screening)
• • 4. Confirmed pregnancy, women of childbearing potential
• • 5. Known hypersensitivity to GLP-1-RA
• • 6. Expected to recover kidney function, stop hemodialysis, pursue palliative care, or transplantation within 6 months
• • 7. Enrolment in another clinical trial judged by the investigator to interact with the effect of GLP1-RA